Pfizer's second-quarter net loss of $248 million is an accounting event, not an operating one. Revenue rose 2.6% to $15,034 million and first-half operating cash flow nearly doubled to $3,450 million, but a $4,325 million non-cash intangible write-off — $3.8 billion of it tied to a single failed Phase 3 readout — dragged pre-tax income to $(653) million. Strip out the write-off, the $1,870 million ViiV disposal gain, restructuring and legal charges, and normalized pre-tax profit still fell 6.1% year over year, because gross margin compressed 1.4 percentage points while R&D spending climbed 13.2%. For a company whose balance sheet carries $118.5 billion of goodwill and intangibles against $85.5 billion of equity, the write-off matters less for what it cost this quarter than for what it signals about the assets still on the books.
1. Consolidated Balance Sheet
1-1. Principal asset movements
| Item | Dec 31, 2025 ($M) | Jun 28, 2026 ($M) | Change |
|---|---|---|---|
| Cash and cash equivalents | 1,142 | 976 | −14.5% |
| Short-term investments | 12,454 | 10,723 | −13.9% |
| Trade accounts receivable, net | 11,874 | 12,490 | +5.2% |
| Inventories | 10,654 | 9,945 | −6.7% |
| Property, plant and equipment, net | 19,317 | 19,029 | −1.5% |
| Identifiable intangible assets, net | 53,731 | 47,053 | −12.4% |
| Goodwill | 71,264 | 71,419 | +0.2% |
| Total assets | 208,160 | 201,131 | −3.4% |
The intangible line tells the story. Net identifiable intangibles fell $6,678 million in six months. Amortization explains $2,368 million of that; the $4,325 million impairment explains most of the rest. Within the balance, indefinite-lived IPR&D dropped from $21,760 million to $17,320 million (−20.4%), reflecting the $3.8 billion write-down plus a $580 million reclassification of Tukysa to developed technology rights.
Liquidity thinned. Cash plus short-term investments fell from $13,596 million to $11,699 million, a 14.0% draw. A large part went to tax: income taxes payable collapsed from $3,103 million to $653 million as Pfizer paid the eighth and final instalment of its $15 billion 2017 repatriation tax liability by its April 15, 2026 due date. That obligation is now retired — a recurring cash drag that disappears from 2027.
Inventories fell 6.7% to $9,945 million while first-half cost of sales rose 15.3% to $7,640 million. On a like-for-like six-month basis that puts inventory at roughly 236 days of cost of sales at June 28, 2026 — but the December 31, 2025 balance sheet in this filing has no matching six-month cost figure, so a clean prior-period days comparison is not available from this 10-Q alone. Receivables grew 5.2% against 3.9% first-half revenue growth, a mild but not alarming divergence.
Goodwill and intangibles together are $118,472 million, or 58.9% of total assets and 1.39 times shareholders' equity. Under US GAAP these carry at historical cost with no upward revaluation, so the existing balance can only shrink — through amortization or further impairment. What can push it back up is new dealmaking: the $8.0 billion Metsera acquisition in November 2025 alone added $2.1 billion of goodwill plus $7.9 billion of IPR&D to the stack, and the goodwill line already moved from $71,264 million to $71,419 million this half as a result. Any future transaction would do the same.
1-2. Debt structure — financial versus operating liabilities
Financial debt totalled $63,194 million (short-term borrowings $2,699 million plus long-term debt $60,495 million), down $1,601 million from $64,795 million. Pfizer issued no new long-term debt in the first half and repaid $1,250 million. But because cash was drawn down harder than debt was repaid, net debt was essentially flat at roughly $51.5 billion versus $51.2 billion.
The maturity wall looks manageable near term. The current portion of long-term debt is $2,607 million of principal — 4.1% of the $62,872 million total principal outstanding. First-half interest expense of $1,336 million against average balances implies an average cost of about 4.2%. One detail is worth noting: the estimated fair value of long-term debt is $58 billion against a $60 billion carrying value. The debt trades below par, meaning Pfizer's existing coupons sit below current market rates — a modest advantage on the existing stack, and a warning about the cost of refinancing it.
Operating liabilities moved the other way. Trade accounts payable fell 12.6% to $4,581 million and accrued compensation fell 29.3% to $2,554 million, the latter consistent with severance payouts under the restructuring programs. Total accrued rebates and other sales-related accruals rose 4.0% to $12,128 million, roughly in line with revenue.
1-3. Capital structure
Paid-in capital (common stock plus additional paid-in capital) rose from $94,950 million to $95,515 million, entirely from share-based payment activity. Retained earnings fell $2,523 million to $112,087 million: first-half net income of $2,440 million was more than consumed by the $4,902 million of dividends declared in the second quarter. Treasury stock was essentially unchanged at $(115,194) million — Pfizer is not buying back shares. Accumulated other comprehensive loss narrowed from $(8,069) million to $(7,218) million on $785 million of favourable foreign currency translation, a dollar-weakness effect rather than an earnings effect.
The picture is a company returning cash through dividends alone, funded partly by retained earnings that are now shrinking.
2. Consolidated Statement of Operations
2-1. Core metrics
| Item | Q2 2024 ($M) | Q2 2025 ($M) | Q2 2026 ($M) | 2Y CAGR |
|---|---|---|---|---|
| Total revenues | 13,283 | 14,653 | 15,034 | +6.4% |
| Pre-tax income (continuing ops) | (103) | 3,044 | (653) | n/m |
| Pre-tax margin | (0.8)% | 20.8% | (4.3)% | — |
| Net income attributable to Pfizer | 41 | 2,910 | (248) | n/m |
| Net margin | 0.3% | 19.9% | (1.6)% | — |
Q2 2024 figures from SEC XBRL filings; Q2 2025 and Q2 2026 from the Q2 2026 Form 10-Q. Pfizer does not report an operating income subtotal, so pre-tax income from continuing operations is used.
Context matters here. Q2 2026 is not an aberration in Pfizer's calendar — Q2 2024 also produced a pre-tax loss, of $(103) million. The second quarter is structurally Pfizer's weakest, because COVID-related product revenue concentrates in the fourth and first quarters.
The revenue mix improved. Product revenues actually fell 0.8% to $11,863 million. Growth came entirely from alliance revenues, up 18.7% to $2,697 million, and royalty revenues, up 11.3% to $474 million. Alliance revenue is Pfizer's share of profits on partnered products such as Eliquis; it carries no cost of sales. That mix shift flatters reported growth while doing nothing for manufacturing scale.
Below the revenue line, the pressure is real. Cost of sales rose 8.3% against 2.6% revenue growth, pushing gross margin from 74.2% to 72.8%. Over the half the gap is wider: cost of sales up 15.3% against revenue up 3.9%, gross margin down from 76.6% to 74.1% — a 2.5 percentage point compression.
Separating one-time from recurring. Reported pre-tax loss of $(653) million includes $4,325 million of asset impairments, $457 million of restructuring and acquisition costs, $842 million of legal charges, and $255 million of contingent consideration remeasurement, offset by the $1,870 million ViiV gain. Adding those back gives a normalized pre-tax profit of roughly $3,356 million, a 22.3% margin. On the same basis, Q2 2025 normalizes to $3,575 million and 24.4%. Revenue grew 2.6% while normalized pre-tax profit fell 6.1% — negative operating leverage. The company is not converting its top-line growth into profit.
The loss per share of $(0.04) is the GAAP figure. Pfizer's headline adjusted diluted EPS of $0.77 excludes the impairments, intangible amortization, restructuring charges and other items discussed above; it is not comparable to the reported number.
2-2. Fixed versus variable cost behaviour
Selling, informational and administrative expenses were flat — $3,411 million against $3,415 million, down 1.1% over the half. That is the restructuring program working: the largely fixed commercial base is being held down while revenue grows.
R&D moved the opposite way, up 13.2% to $2,809 million in the quarter and 13.1% to $5,299 million over the half. R&D intensity rose from 16.9% to 18.7% of revenue. Reported R&D is also understated: a June 2026 funding arrangement with Abingworth, worth up to $300 million through 2029, reduced second-quarter R&D by $26 million. Underlying spend grew slightly faster than the reported figure.
The two lines net out to a squeeze. Fixed commercial cost discipline is being spent on R&D and lost to gross margin, leaving nothing for the bottom line.
3. Consolidated Statement of Cash Flows
| Item (six months) | H1 2025 ($M) | H1 2026 ($M) | Change |
|---|---|---|---|
| Net cash from operating activities | 1,753 | 3,450 | +96.8% |
| Net cash from investing activities | 7,225 | 2,891 | −60.0% |
| Net cash from financing activities | (8,423) | (6,519) | — |
| Cash at end of period | 1,694 | 1,034 | −39.0% |
Operating cash flow nearly doubled. Capital expenditure fell 18.0% to $969 million, so free cash flow (operating cash flow less capex) reached $2,481 million against $571 million a year earlier. Capex ran at 3.3% of revenue, down from 4.2% — maintenance-level spending, not expansion.
Quality of earnings improved sharply. Operating cash flow to net income was 1.40× in H1 2026, against 0.30× in H1 2025 and −0.22× in H1 2024. Above 1.0× is the normal standard, and Pfizer has cleared it in a first half for the first time in three years. On a full-year basis the ratio has stayed comfortably above 1.0× — FY2025 operating cash flow was $11,704 million — so the improvement here is a first-half seasonality normalization, not a multi-year deterioration reversed. The caveat is that the ratio still flatters this half: net income was suppressed by non-cash write-offs and impairments of $4,425 million on the cash flow statement — the $4,325 million intangible impairment plus $100 million of other write-offs — all of which cash flow correctly ignores.
The cash gap is on the distribution side. Pfizer paid $4,896 million in dividends in the half against $2,481 million of free cash flow. That does not annualize cleanly — Pfizer's cash generation is heavily second-half weighted, with full-year 2025 operating cash flow of $11,704 million against just $1,753 million in the first half. But at a run-rate of roughly $9.8 billion a year, the dividend absorbs most of what the business generates, which is why the buyback is dormant and why the ViiV disposal proceeds of $1,875 million went to plugging the first-half gap rather than to shareholders.
Investing cash flow fell because the prior year included $6,311 million from the Haleon share sales. Those non-core disposals are now largely exhausted.
4. What Deserves Attention
The write-off is a pipeline verdict, not a bookkeeping choice. The $3.8 billion IPR&D impairment came from a Phase 3 study of sigvotatug vedotin in second-line metastatic non-squamous non-small cell lung cancer, following unfavourable trial results. That asset arrived through the Seagen acquisition. The remaining $525 million wrote off Oxbryta developed technology rights after Pfizer engaged with the FDA in July 2026 and concluded there was no viable pathway to return the sickle-cell drug to the US market; it notified the FDA on July 31, 2026 that it was voluntarily withdrawing the NDAs. Both were decisions about specific science, not accounting estimates. With $17,320 million of IPR&D still on the balance sheet — 36.8% of net intangibles — the portfolio's continued exposure to binary clinical outcomes means the Q2 2026 write-down may not be the last.
Disclaimer: This report is based on Pfizer Inc.'s Q2 2026 Form 10-Q filed with the SEC. It is provided for informational purposes only and does not constitute investment advice or a solicitation to buy or sell any security. LineVest News is an independent publication and is not a registered investment adviser.